Back
Lipocine, Inc. 10K Form
Buy
67
LPCN
Lipocine, Inc.
Last Price:
$3.11
Seasonality Move:
-5.53%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-09 | 10Q | LPCN/Lipocine, Inc. Quarterly |
| 2023-11-08 | 10Q | LPCN/Lipocine, Inc. Quarterly |
| 2023-08-10 | 10Q | LPCN/Lipocine, Inc. Quarterly |
| 2023-05-11 | 10Q | LPCN/Lipocine, Inc. Quarterly |
| 2022-11-09 | 10Q | LPCN/Lipocine, Inc. Quarterly |
| 2022-08-08 | 10Q | LPCN/Lipocine, Inc. Quarterly |
Receive LPCN News And Ratings
See the #1 stock for the next 7 days that we like better than LPCN
LPCN Financial Statistics
Sales & Book Value
| Annual Sales: | $11.2M |
|---|---|
| Cash Flow: | $-3M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $2.61 |
| Price / Book: | 1.22 |
Profitability
| EPS (TTM): | -1.01630 |
|---|---|
| Net Income (TTM): | $-5.5M |
| Gross Margin: | $11.2M |
| Return on Equity: | -30.22% |
| Return on Assets: | -27.83% |
Lipocine, Inc. Earnings Forecast
Key Lipocine, Inc. Financial Ratios
-
The Gross Profit Margin over the past 12 years for LPCN is 99.63%.
-
The Selling, General & Administrative Expenses for LPCN have been equal to 44.66% of Gross Profit Margin.
-
The Research & Development expenses have been 65.28% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of LPCN is 0.08% of Total Revenues.
-
Per Share Earnings over the last 14 years have been positive in 7 years.
Lipocine, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | LPCN |
| CUSIP: | 53630X |
| Website: | lipocine.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 8.25 |
| Quick Ratio: | 7.84 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
LPCN Technical Analysis vs Fundamental Analysis
Buy
67
Lipocine, Inc. (LPCN)
is a Buy
Is Lipocine, Inc. a Buy or a Sell?
-
Lipocine, Inc. stock is rated a BuyThe current Lipocine, Inc. [LPCN] share price is $3.10. The Score for LPCN is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.